Alabama is currently home to 1237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease - A Randomized Controlled Trial
NCT06089135
Recruiting
The Short-Cut trial is a prospective, investigator-initiated, multicenter, randomized controlled trial that is designed to compare the efficacy of cutting balloon angioplasty vs. intravascular lithotripsy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/03/2025
Locations: UAB Structural Heart and Valve Clinic, Birmingham, Alabama
Conditions: Treatment in Calcified Coronary Disease
Register for Updates
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201
Recruiting
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/02/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Multiple Sclerosis, Myasthenia Gravis
Register for Updates
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199
Recruiting
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/02/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Plaque Psoriasis
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589
Recruiting
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Gender:
ALL
Ages:
Between 5 years and 11 years
Trial Updated:
04/02/2025
Locations: Research Site, Montgomery, Alabama
Conditions: Asthma
Register for Updates
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064
Recruiting
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
04/02/2025
Locations: Alkermes Investigator Site, Dothan, Alabama
Conditions: Schizophrenia, Bipolar I Disorder
Register for Updates
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
NCT06101329
Recruiting
The goal of this clinical study is to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for prevention of HIV in the cisgender women in the US. The primary objectives of this study are: 1) to characterize the pharmacokinetics (PK) of LEN in United States (US) cisgender women; 2) to evaluate the safety of LEN and F/TDF for pre-exposure prophylaxis (PrEP) in US cisgender women; and 3) to evaluate the gener... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: UAB, 1917 Research Clinic, Birmingham, Alabama
Conditions: Pre-Exposure Prophylaxis of HIV Infection
Register for Updates
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT06045754
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab together with ustekinumab in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/01/2025
Locations: Digestive Health Specialsits, Dothan, Alabama
Conditions: Crohn's Disease
Register for Updates
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT05868226
Recruiting
I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama
Conditions: HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
Register for Updates
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
Recruiting
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Stage III Colon Cancer
Register for Updates
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
NCT05164341
Recruiting
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/01/2025
Locations: University of Alabama, Birmingham, Alabama
Conditions: Partial Lipodystrophy
Register for Updates
Strengthening Health and Insight in New Educators
NCT06745934
Recruiting
Teachers are at notable risk for depression and anxiety. The present study tests an app-based mindfulness intervention for teachers in their final year of training with the goal of preventing the deterioration of their mental health during the transition into the classroom. The project will strengthen the research environment at the University of Alabama and will involve undergraduate research assistants in each step of the research process.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of Alabama, Tuscaloosa, Alabama
Conditions: Anxiety Symptoms, Depressive Symptoms
Register for Updates
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498
Recruiting
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates